Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

Stephen Jolles, Mikhail A. Rojavin, John Philip Lawo, Robert Nelson, Richard L. Wasserman, Michael Borte, Michael A. Tortorici, Kohsuke Imai, Hirokazu Kanegane

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual studies of small patient numbers. Seven open-label, Phase 3, prospective, multicenter studies of the efficacy and safety of Hizentra® (a SCIG), conducted in Japan, Europe, and the US were summarized. Overall, 125 unique patients received 15,013 weekly infusions during a total observation period of 250.9 patient-years. Mean weekly doses of Hizentra® were 83.22–221.3 mg/kg body weight; infusion rates per patient (total body rate) were 25.2–49.3 mL/h across studies. The rates of infections and serious bacterial infections were 3.10 and 0.03 events per patient/year, respectively. Annualized rates of days hospitalized due to infection, out of work/school, and prophylactic antibiotic use were 0.95, 5.14, and 36.78 per patient, respectively. For the equivalent monthly dose, weekly Hizentra® SCIG administration resulted in expectedly-increased serum IgG trough levels in patients switching from IVIG, and maintained levels in patients switching from previous SCIG. Adverse events (AEs) totaled 5039 (events/infusion 0.094–0.773), almost all of which were mild/moderate. Three thousand one hundred ninety-seven were considered treatment-related, the most common of which were injection site reactions (2919 events; 0.001–0.592 AEs per infusion). Systemic AEs were very uncommon. The results from these seven studies indicate that Hizentra® therapy was both efficacious and well tolerated during long-term treatment. This is particularly important in patients with PID, who may require lifelong IgG replacement therapy.

Original languageEnglish (US)
JournalJournal of Clinical Immunology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Japan
Immunoglobulin G
Safety
Hizentra
Therapeutics
Intravenous Immunoglobulins
Infection
Bacterial Infections
Multicenter Studies
Body Weight
Observation
Prospective Studies
Anti-Bacterial Agents
Injections
Serum

Keywords

  • Immunoglobulin G replacement therapy
  • IVIG
  • primary antibody deficiencies
  • primary immunodeficiencies
  • SCIG

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States : a Review of 7 Phase 3 Trials. / Jolles, Stephen; Rojavin, Mikhail A.; Lawo, John Philip; Nelson, Robert; Wasserman, Richard L.; Borte, Michael; Tortorici, Michael A.; Imai, Kohsuke; Kanegane, Hirokazu.

In: Journal of Clinical Immunology, 01.01.2018.

Research output: Contribution to journalArticle

Jolles, Stephen ; Rojavin, Mikhail A. ; Lawo, John Philip ; Nelson, Robert ; Wasserman, Richard L. ; Borte, Michael ; Tortorici, Michael A. ; Imai, Kohsuke ; Kanegane, Hirokazu. / Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States : a Review of 7 Phase 3 Trials. In: Journal of Clinical Immunology. 2018.
@article{f560461bcae14d6299384a454be0a6ad,
title = "Long-Term Efficacy and Safety of Hizentra{\circledR} in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials",
abstract = "Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual studies of small patient numbers. Seven open-label, Phase 3, prospective, multicenter studies of the efficacy and safety of Hizentra{\circledR} (a SCIG), conducted in Japan, Europe, and the US were summarized. Overall, 125 unique patients received 15,013 weekly infusions during a total observation period of 250.9 patient-years. Mean weekly doses of Hizentra{\circledR} were 83.22–221.3 mg/kg body weight; infusion rates per patient (total body rate) were 25.2–49.3 mL/h across studies. The rates of infections and serious bacterial infections were 3.10 and 0.03 events per patient/year, respectively. Annualized rates of days hospitalized due to infection, out of work/school, and prophylactic antibiotic use were 0.95, 5.14, and 36.78 per patient, respectively. For the equivalent monthly dose, weekly Hizentra{\circledR} SCIG administration resulted in expectedly-increased serum IgG trough levels in patients switching from IVIG, and maintained levels in patients switching from previous SCIG. Adverse events (AEs) totaled 5039 (events/infusion 0.094–0.773), almost all of which were mild/moderate. Three thousand one hundred ninety-seven were considered treatment-related, the most common of which were injection site reactions (2919 events; 0.001–0.592 AEs per infusion). Systemic AEs were very uncommon. The results from these seven studies indicate that Hizentra{\circledR} therapy was both efficacious and well tolerated during long-term treatment. This is particularly important in patients with PID, who may require lifelong IgG replacement therapy.",
keywords = "Immunoglobulin G replacement therapy, IVIG, primary antibody deficiencies, primary immunodeficiencies, SCIG",
author = "Stephen Jolles and Rojavin, {Mikhail A.} and Lawo, {John Philip} and Robert Nelson and Wasserman, {Richard L.} and Michael Borte and Tortorici, {Michael A.} and Kohsuke Imai and Hirokazu Kanegane",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10875-018-0560-5",
language = "English (US)",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",

}

TY - JOUR

T1 - Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States

T2 - a Review of 7 Phase 3 Trials

AU - Jolles, Stephen

AU - Rojavin, Mikhail A.

AU - Lawo, John Philip

AU - Nelson, Robert

AU - Wasserman, Richard L.

AU - Borte, Michael

AU - Tortorici, Michael A.

AU - Imai, Kohsuke

AU - Kanegane, Hirokazu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual studies of small patient numbers. Seven open-label, Phase 3, prospective, multicenter studies of the efficacy and safety of Hizentra® (a SCIG), conducted in Japan, Europe, and the US were summarized. Overall, 125 unique patients received 15,013 weekly infusions during a total observation period of 250.9 patient-years. Mean weekly doses of Hizentra® were 83.22–221.3 mg/kg body weight; infusion rates per patient (total body rate) were 25.2–49.3 mL/h across studies. The rates of infections and serious bacterial infections were 3.10 and 0.03 events per patient/year, respectively. Annualized rates of days hospitalized due to infection, out of work/school, and prophylactic antibiotic use were 0.95, 5.14, and 36.78 per patient, respectively. For the equivalent monthly dose, weekly Hizentra® SCIG administration resulted in expectedly-increased serum IgG trough levels in patients switching from IVIG, and maintained levels in patients switching from previous SCIG. Adverse events (AEs) totaled 5039 (events/infusion 0.094–0.773), almost all of which were mild/moderate. Three thousand one hundred ninety-seven were considered treatment-related, the most common of which were injection site reactions (2919 events; 0.001–0.592 AEs per infusion). Systemic AEs were very uncommon. The results from these seven studies indicate that Hizentra® therapy was both efficacious and well tolerated during long-term treatment. This is particularly important in patients with PID, who may require lifelong IgG replacement therapy.

AB - Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual studies of small patient numbers. Seven open-label, Phase 3, prospective, multicenter studies of the efficacy and safety of Hizentra® (a SCIG), conducted in Japan, Europe, and the US were summarized. Overall, 125 unique patients received 15,013 weekly infusions during a total observation period of 250.9 patient-years. Mean weekly doses of Hizentra® were 83.22–221.3 mg/kg body weight; infusion rates per patient (total body rate) were 25.2–49.3 mL/h across studies. The rates of infections and serious bacterial infections were 3.10 and 0.03 events per patient/year, respectively. Annualized rates of days hospitalized due to infection, out of work/school, and prophylactic antibiotic use were 0.95, 5.14, and 36.78 per patient, respectively. For the equivalent monthly dose, weekly Hizentra® SCIG administration resulted in expectedly-increased serum IgG trough levels in patients switching from IVIG, and maintained levels in patients switching from previous SCIG. Adverse events (AEs) totaled 5039 (events/infusion 0.094–0.773), almost all of which were mild/moderate. Three thousand one hundred ninety-seven were considered treatment-related, the most common of which were injection site reactions (2919 events; 0.001–0.592 AEs per infusion). Systemic AEs were very uncommon. The results from these seven studies indicate that Hizentra® therapy was both efficacious and well tolerated during long-term treatment. This is particularly important in patients with PID, who may require lifelong IgG replacement therapy.

KW - Immunoglobulin G replacement therapy

KW - IVIG

KW - primary antibody deficiencies

KW - primary immunodeficiencies

KW - SCIG

UR - http://www.scopus.com/inward/record.url?scp=85056343487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056343487&partnerID=8YFLogxK

U2 - 10.1007/s10875-018-0560-5

DO - 10.1007/s10875-018-0560-5

M3 - Article

C2 - 30415311

AN - SCOPUS:85056343487

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

ER -